LRRK2 and Parkinson disease: In keeping with this, in asymptomatic mutation LRRK2 carriers, DAT reduction was found to be more pronounced than changes in VMAT2 and L-AADC indicating in vivo a strong involvement of compensatory DAT down-regulation in the pre-symptomatic stage of PD aiming to delay onset of clinical symptoms [82].